Patients with hepatitis C genotype 1b and chronic kidney disease who received AbbVie's Viekirax, or ombitasvir, paritaprevir and ritonavir, had similar rates of rapid virologic response, end of treatment response and sustained virologic response, compared with those without CKD, researchers reported in Hepatology Research. The findings also showed similar prevalence of treatment-emergent adverse events between both groups.
Researchers evaluate AbbVie's hepatitis drug in HCV patients with CKD
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.